A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

(2009) Sandrine Faivre et al.   LANCET ONCOLOGY

Hypertension and proteinuria: a class-effect of antiangiogenic therapies

(2008) Vincent Launay-Vacher et al.   ANTI-CANCER DRUGS

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients

(2008) E Rouits et al.   BRITISH JOURNAL OF CANCER

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics

(2008) John F. Deeken et al.   CANCER

Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

(2008) Mark A. Socinski et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors

(2008) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST

Pharmacogenetics in colorectal cancer: a systematic review

(2008) Silvia Funke et al.   PHARMACOGENOMICS